Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

Next Previous
Trial Profile

A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perampanel (Primary)
  • Indications Absence epilepsy; Complex partial epilepsy; Epilepsy; Generalised seizures; Myoclonic epilepsies; Partial epilepsies; Tonic-clonic epilepsy
  • Focus Therapeutic Use
  • Acronyms PROVE; Study 506
  • Sponsors Eisai Inc

    • Most Recent Events

    • 27 Apr 2023 Results of pooled analysis of PERMIT and PROVE assessing perampanel when used in everyday clinical practice, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
    • 20 Apr 2023 According to a Catalyst Pharmaceuticals media release, abstract will be presented at the upcoming AAN 2023 Annual Meeting taking place in Boston, MA and virtually on April 22-27, 2023.
    • 20 Apr 2023 According to a Catalyst Pharmaceuticals media release, data from this study (to be presented in AAN 2023) is presented online https://index.mirasmart.com/aan2023/PDFfiles/AAN2023-002293.html.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top